- Home
- PRQR vs BGH Comparison
PRQR vs BGH Comparison
Compare PRQR & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- BGH
- Stock Information
- Founded
- PRQR 2012
- BGH 2012
- Country
- PRQR Netherlands
- BGH United States
- Employees
- PRQR N/A
- BGH N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- BGH Investment Managers
- Sector
- PRQR Health Care
- BGH Finance
- Exchange
- PRQR Nasdaq
- BGH Nasdaq
- Market Cap
- PRQR 309.5M
- BGH 318.8M
- IPO Year
- PRQR 2014
- BGH N/A
- Fundamental
- Price
- PRQR $1.72
- BGH $14.44
- Analyst Decision
- PRQR Strong Buy
- BGH
- Analyst Count
- PRQR 7
- BGH 0
- Target Price
- PRQR $9.00
- BGH N/A
- AVG Volume (30 Days)
- PRQR 573.8K
- BGH 61.5K
- Earning Date
- PRQR 05-08-2025
- BGH 01-01-0001
- Dividend Yield
- PRQR N/A
- BGH 10.06%
- EPS Growth
- PRQR N/A
- BGH N/A
- EPS
- PRQR N/A
- BGH N/A
- Revenue
- PRQR $21,212,711.00
- BGH N/A
- Revenue This Year
- PRQR $2.87
- BGH N/A
- Revenue Next Year
- PRQR N/A
- BGH N/A
- P/E Ratio
- PRQR N/A
- BGH N/A
- Revenue Growth
- PRQR 85.91
- BGH N/A
- 52 Week Low
- PRQR $1.07
- BGH $11.92
- 52 Week High
- PRQR $4.62
- BGH $14.50
- Technical
- Relative Strength Index (RSI)
- PRQR 56.89
- BGH 46.93
- Support Level
- PRQR $1.47
- BGH $14.41
- Resistance Level
- PRQR $1.82
- BGH $14.89
- Average True Range (ATR)
- PRQR 0.13
- BGH 0.13
- MACD
- PRQR 0.01
- BGH 0.01
- Stochastic Oscillator
- PRQR 44.95
- BGH 29.69
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.